Contrast Research Of Anti-inflammatory Effects Of Cilostazol And Clopidogrel In Patients With ACS

Objective:To explore the role and mechanism of cilostazol and clopidogrel to acute coronary syndrome patients in plaque stability and inflammation suppression function,as well as their synergism with statins.Methods:82 selected patients were divided randomly into three groups:the basic treatment group(conventional medication plus atorvastatin),the cilostazol group (basic treatment plus cilostazol)the clopidogrel group(basic treatment plus clopidogrel).The change of some indicator levels,including leukocyte count,blood lipids,tumor-necrosis factor-α,interleukin-1β,high-sensitivity C-reactive protein was measured aider three weeks of treatment.Clinical therapeutic effect and adverse reactions were monitored.Results:①After the treatment,the serum levels of white blood cell,cholesterol, triglycerides and low densitylipoprotein in three groups decreased slightly(P＜0.05),but there was no significance among the three groups.②The increase of high densitylipoprotein was observed in the three groups,but the increased degree was significantly higher in the cilostazol group than in the others(P＜0.01).③The serum levels of TNF-α,IL-1β,Hs-CRP declined in the three groups(P＜0.05),but the degree of reduction of them was greater in the cilostazol and clopidogrel group than in the basic treatment group(P＜0.05).④The reduction of TNF-αand IL-1βwas negatively correlated with the increase of high densitylipoprotein in the cilostazol group(r=-0.38,P=0.04;r=-0.39,P=0.03).⑤cilostazol and clopidogrel could obviously ease chest pain with no adverse effect.Conclusion:The use of cilostazol or clopidogrel joint atorvastatin on the basis of conventional treatment,compared with atorvastatin alone,could further reduce the serum levels of inflammatory cytokines,inhibiting platelet activation and promote plaque stability,safe and reliable;cilostazol which can also increase HDL.play better synergies with statins.